



Thursday, August 31, 2006

Dear Fellow Shareholders of Nutra Pharma,

Thank you for your continued support of our Company. I am pleased to announce that on June 30<sup>th</sup>, Nutra Pharma successfully completed the second quarter of our fiscal year. Not only was this past quarter filled with numerous significant research and development accomplishments, but this quarter also represents our first revenue producing quarter ever at Nutra Pharma. This completes the transition of Nutra Pharma from a research and development company to a commercial enterprise.

In May, ReceptoPharm, our drug discovery arm, received approval by the British Medicines Health and Regulatory Agency (MHRA) for its application of human clinical trials for the treatment of Adrenomyeloneuropathy (AMN). The MHRA is the medical regulatory agency within the British Department of Health. We expect the trial to commence this fall.

In addition, this past June, ReceptoPharm signed a letter of intent to be fully acquired by Nutra Pharma. Currently Nutra Pharma owns 38.1% of ReceptoPharm. The merger will provide Nutra Pharma with 100% of the outstanding ReceptoPharm stock and complete ownership of the ReceptoPharm intellectual property. We believe that the merger will be completed during the fourth quarter of 2006.

This past March, Nutra Pharma launched Designer Diagnostics, a company specializing in the marketing and sales of diagnostics test kits for the rapid identification of Tuberculosis and NonTuberculosis Mycobacterium. We are pleased to announce that Designer Diagnostics has already generated revenue for the Company.

Additionally, Designer Diagnostics is building partnerships with a number of medical equipment distributors in Europe and Asia to bring their products to market in those regions. With these partnerships, it is our estimation that Designer Diagnostics will achieve triple-digit growth in the fourth quarter.

As part of the ongoing efforts of our investor relations and corporate communications initiatives, we have implemented a number of new services for our shareholders. To help us with our ongoing improvements, please visit our investor relations homepage, accessible online at [www.NutraPharma.com](http://www.NutraPharma.com), to participate in an investor relations feedback survey. We have also received requests for literature about our Company. In response, we are developing a corporate media kit, which should be mailing within 6-8 weeks. To request a media kit, please visit our website and click on the "email alerts" link.

Our email list has continued to grow since last quarter and we recommend that all shareholders signup for our email alerts to receive the most up-to-date information available from Nutra Pharma. Investors may signup by visiting our homepage at [www.NutraPharma.com](http://www.NutraPharma.com) and clicking on the "email alerts" link.

Again, we thank you for your continued support. If you have any questions or would like additional information, please contact our investor relations hotline toll-free at (877) 895-5647.

Sincerely yours,

Rik J. Deitsch  
Chairman and Chief Executive Officer  
Nutra Pharma Corporation  
Ticker Symbol: OTC: NPHC